Rituximab Biosimilar Market report on 35+ companies and 35+ marketed and pipeline drugs by DelveInsight

(Albany, USA)– Rituximab Biosimilar Market report on 35+ companies and 35+ marketed and pipeline drugs by DelveInsight

“Rituximab Biosimilar Insight, 2020” by DelveInsight covers the marketed and pipeline drug profiles, including clinical and non-clinical stage products with Global coverage. It also includes the therapeutics assessment by product type, stage, route of administration, and molecule type. It further showcases the inactive pipeline products in this space.

Rituximab Biosimilar Report Highlights

• Companies and academics are working to evaluate challenges and seek opportunities that could influence Rituximab R&D.
• Pfizer announced regarding the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) had adopted a positive opinion, recommending marketing authorization for RUXIENCE (rituximab), a potential biosimilar to MabThera (rituximab) in January 2019.
• Amgen and Allergan declared the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 798, a biosimilar candidate to Rituxan (rituximab) in December 2019. Amgen and Allergan are teaming up four oncology biosimilar medicines; FDA had already approved two of them.
• Teva Pharmaceuticals and Celltrion Healthcare, in November 2019, stated that TRUXIMA (rituximab-abbs) injection is the first biosimilar to the reference product Rituxan1 (rituximab) now available in the United States with a full oncology label.

View Report: https://www.delveinsight.com/report-store/rituximab-biosimilars-insight

Rituximab is a type of antibody therapy, which can be used alone or with chemotherapy. They work in different ways to catch and attack the cells where cancer occurs. Rituximab targets and attaches to the CD20 protein found on the surface of blood cells with cancer and some healthy blood cells. Rituximab is used for treating certain types of cancer. It works by reducing or prohibiting the growth of cancer cells. This drug is also used for treatment of certain types of blood vessel disease, decrease the swelling of the blood vessels, and treat a specific skin condition.

DelveInsight’s report provides analysis of several drugs in different clinical development stages, covering marketed, phase III, II, I, and preclinical. It also helps to comprehend clinical trial details, expressive pharmacological action, agreements, and collaborations.

Have a query? Ask our Experts @ https://www.delveinsight.com/sample-request/rituximab-biosimilars-insight

Rituximab Biosimilars Marketed Drugs

• Blitzima by Celltrion

Blitzima is a medicine used for treating blood cancers and inflammatory conditions in adults. The drug may be given with chemotherapy (other cancer medicines) or medicines used for inflammatory disorders (corticosteroids). Blitzima contains the active substance rituximab.

• Rixathon by Sandoz

Rixathon is approved for non-Hodgkin’s lymphoma and chronic lymphocytic leukemia, as well as immunological diseases. This drug may be given on its own or with chemotherapy or medicines used for inflammatory disorders.

For further product details, contact here @ https://www.delveinsight.com/sample-request/rituximab-biosimilars-insight

View Report: https://www.delveinsight.com/report-store/rituximab-biosimilars-insight

Rituximab Biosimilars Emerging Drugs

• IBI301 by Innovent Biologics

IBI301 is a potential biosimilar of rituximab, a recombinant human-mouse chimeric anti-CD20 monoclonal antibody for injection, and co-developed by Eli Lilly and Company and Innovent. Rituximab attaches to the CD20 antigen on the surface of B lymphocytes and facilitates complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC). Normal and malignant B cells are aimed for damage by the antibody, hence attaining anti-tumor and immunosuppressive therapeutic effects.

• ABP 798 by Allergan/Amgen

ABP 798 has been developed as a biosimilar candidate to Rituxan. Rituxan is an anti-CD20 monoclonal antibody, which has been approved in many areas, for adult patients alone or in combination with chemotherapy, treating non-Hodgkin’s lymphoma, in combination with fludarabine and cyclophosphamide for chronic lymphocytic leukemia, granulomatosis with polyangiitis and microscopic polyangiitis with glucocorticoids. The active ingredient of ABP 798 is a monoclonal antibody with the same amino acid sequence as Rituxan.

For more product profiles, request sample pages @ https://www.delveinsight.com/sample-request/rituximab-biosimilars-insight

View Report: https://www.delveinsight.com/report-store/rituximab-biosimilars-insight

Rituximab Biosimilars Drugs covered in the report:-

• IBI-301
• RGB 03
• RITUMAX
•  ABP 798
•  AcellBia/Usmal
• Blitzima/Truxima
• BX 2336
•  DRL_RI
•  GP2013
• HLX01
• iBio Rituximab
• IBPB 001RX
• MK-8808
•  Ritemvia/Blitzima
• Riximyo
• RTXM83
• Ruxience
•  AP 052
•  Retuxira
•  TL-011
•  RituxiRel
•  Kikuzubam
•  LBRx
•  DRL-rituximab
• MG1106
•  GB-241
•  Rilast
•  HS 006
• BX 2336
• GNR-006

Scope of Rituximab Biosimilars report:

• Major Players in Rituximab –  35+ key companies
• Phases – 35+ products under different phases of clinical development
  •  Marketed stage products
  •  Late-stage products (BLA Filed and Phase III)
  •  Mid-stage products (Phase II)
  •  Early-stage products (Phase I)
  •  Pre-clinical and Discovery stage candidates
  •  Discontinued & Inactive candidates
  •  Route of Administration

•  Route of Administration     
  • Subcutaneous
  • Intravenous
  • Molecule Type
• Molecule types
  • Monoclonal antibodies
  • Peptide
  • Protein
  • Small molecule
  • Product Type

Product Types

• Mono
• Combination
• Mono/Combination

Key Questions Answered in the report:-

• How many key companies are developing Rituximab Biosimilars?
• How many Rituximab biosimilars are developed by each key player?
• How many emerging biosimilars are in mid-stage and late-stage?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities pertinent to the Rituximab biosimilars therapeutics?
•  What are the clinical studies going on for Rituximab biosimilars and their status?
•  What are the main designations that have been granted to emerging drugs?

 Table of Contents

Browse Detailed TOC, Emerging Drugs and Companies @ https://www.delveinsight.com/sample-request/rituximab-biosimilars-insight

Request a WebEx Walkthrough of the Report: https://www.delveinsight.com/sample-request/rituximab-biosimilars-insight

View Report: https://www.delveinsight.com/report-store/rituximab-biosimilars-insight

Related Reports 

• Filgrastim Biosimilar Insight

DelveInsight’s, “Filgrastim– Biosimilar Insight, 2020,” report provides comprehensive insights about 20+ companies and 20+ marketed and pipeline drugs in the Filgrastim Biosimilars landscape.

Access here @ https://www.delveinsight.com/report-store/filgrastim-biosimilar-insight 

• Interferon Biosimilar Insight

DelveInsight’s, “Interferon– Biosimilar Insight, 2020,” report provides comprehensive insights about 10+ companies and 10+ marketed and pipeline drugs in the Interferon Biosimilars landscape.

Access here @ https://www.delveinsight.com/report-store/interferon-biosimilar-insight 

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
Phone: +19193216187
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/